The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Arcus Biosciences Inc | COM | 03969F109 | 51,726 | 1,842,077 | SH | SOLE | 1,842,077 | 0 | 0 | ||
Coupang Inc | CL A | 22266T109 | 225,262 | 4,564,571 | SH | SOLE | 4,564,571 | 0 | 0 | ||
Novocure Ltd | ORD SHS | G6674U108 | 46,380 | 350,884 | SH | SOLE | 350,884 | 0 | 0 | ||
Oric Pharmaceuticals Inc | COM | 68622P109 | 24,686 | 1,007,575 | SH | SOLE | 1,007,575 | 0 | 0 | ||
Oyster Point Pharma Inc | COM | 69242L106 | 50,610 | 2,768,586 | SH | SOLE | 2,768,586 | 0 | 0 | ||
Unity Biotechnology Inc | COM | 91381U101 | 6,570 | 1,094,998 | SH | SOLE | 1,094,998 | 0 | 0 | ||
Yext Inc | COM | 98585N106 | 31,085 | 2,146,785 | SH | SOLE | 2,146,785 | 0 | 0 |